Artelo Biosciences, Inc.

NasdaqCM ARTL

Artelo Biosciences, Inc. Price to Sales Ratio (P/S) on February 06, 2025

Artelo Biosciences, Inc. Price to Sales Ratio (P/S) is NA on February 06, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Artelo Biosciences, Inc. 52-week high Price to Sales Ratio (P/S) is NA on February 06, 2025, which is NA below the current Price to Sales Ratio (P/S).
Artelo Biosciences, Inc. 52-week low Price to Sales Ratio (P/S) is NA on February 06, 2025, which is NA below the current Price to Sales Ratio (P/S).
Artelo Biosciences, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is NA.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: ARTL

Artelo Biosciences, Inc.

CEO	Mr. Gregory D. Gorgas M.B.A.
IPO Date	June 21, 2019
Location	United States
Headquarters	505 Lomas Santa Fe
Employees	5
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Cosmetics Mental Health Pet Food Pharmaceuticals Vaccines

Description

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Key trends

Past 5 years